Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3W2OE)

• Drug Name: Lauryl Dimethylamine-N-Oxide Drug Info
• Synonyms: 1643-20-5; Lauramine oxide; Lauryldimethylamine oxide; Lauryldimethylamine N-oxide; Dodecyldimethylamine oxide; LDAO; Empigen OB; Ammonyx LO; Ammonyx AO; Aromox DMCD; Conco XAL; Dimethyldodecylamine oxide; Dimethylaurylamine oxide; 1-Dodecanamine, N,N-dimethyl-, N-oxide; DDNO; n-Dodecyldimethylamine oxide; Dodecyldimethylamine N-oxide; dodecyl(dimethyl)amine oxide; Dimethyldodecylamine N-oxide; N,N-dimethyldodecan-1-amine oxide; LAURYL DIMETHYLAMINE-N-OXIDE; Aromox dmmc-W; Dimethyllaurylamine oxide; Amonyx AO; Refan [Russian]

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 15433
  ChEBI ID: CHEBI:131762
  CAS Number: CAS 1643-20-5
  TTD Drug ID: DM3W2OE

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[2]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[3]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[4]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[5]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[7]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[6]
Dihydroorotate	DM76BGZ	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Rhodopsin (RHO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
Phosphonothreonine	DMTFHPI	Discovery agent	N.A.	Investigative	[1]
Beta-D-Mannose	DMHIG9K	Discovery agent	N.A.	Investigative	[1]
Hexadecanoic acid	DMWUXDZ	Discovery agent	N.A.	Investigative	[1]
NSC-88915	DM9WIHJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[9]
B-2-Octylglucoside	DMEGX8H	Discovery agent	N.A.	Investigative	[1]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[1]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[11]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[12]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[13]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[14]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[15]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[16]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[17]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[18]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[19]
Budipine	DMODHQI	Migraine	8A80	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[1]
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[1]
Rhodopsin (RHO)	TTH0KSX	OPSD_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [3] Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
• [4] Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
• [5] Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
• [6] Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
• [7] Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
• [8] Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
• [9] Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
• [10] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [11] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [12] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [13] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [15] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [16] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [17] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [18] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [20] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.